255 related articles for article (PubMed ID: 10953328)
21. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
[TBL] [Abstract][Full Text] [Related]
22. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
[TBL] [Abstract][Full Text] [Related]
23. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
[TBL] [Abstract][Full Text] [Related]
24. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens.
Cheng MF; Chatterjee S; Berger NA
Oncol Res; 1994; 6(6):269-79. PubMed ID: 7865902
[TBL] [Abstract][Full Text] [Related]
25. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.
Hazlehurst LA; Argilagos RF; Emmons M; Boulware D; Beam CA; Sullivan DM; Dalton WS
Cancer Res; 2006 Feb; 66(4):2338-45. PubMed ID: 16489039
[TBL] [Abstract][Full Text] [Related]
26. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F
Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905
[TBL] [Abstract][Full Text] [Related]
27. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
[TBL] [Abstract][Full Text] [Related]
28. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.
Lau DH; Ross KL; Sikic BI
Cancer Res; 1990 Jul; 50(13):4056-60. PubMed ID: 2162251
[TBL] [Abstract][Full Text] [Related]
29. Correlation between DNA topoisomerase II activity and cytotoxicity in pMC540 and merodantoin sensitive and resistant human breast cancer cells.
Sharma R; Arnold L; Gulliya KS
Anticancer Res; 1995; 15(2):295-304. PubMed ID: 7762997
[TBL] [Abstract][Full Text] [Related]
30. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin.
Christodoulopoulos G; Muller C; Salles B; Kazmi R; Panasci L
Cancer Res; 1998 May; 58(9):1789-92. PubMed ID: 9581813
[TBL] [Abstract][Full Text] [Related]
32. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Harris LN; Yang L; Liotcheva V; Pauli S; Iglehart JD; Colvin OM; Hsieh TS
Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
34. [Mechanisms of drug resistance of two cell lines of human chronic promyelocytic leukemia K562, resistant to DNA topoisomerase II inhibitors adriamycin and etoposide].
Meliksetian MB; Berezkina EV; Pavlenko MA; Grinchuk TM
Tsitologiia; 1999; 41(7):615-21. PubMed ID: 10496023
[TBL] [Abstract][Full Text] [Related]
35. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
[TBL] [Abstract][Full Text] [Related]
36. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
[TBL] [Abstract][Full Text] [Related]
37. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.
Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK
Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151
[TBL] [Abstract][Full Text] [Related]
38. Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78.
Chatterjee S; Hirota H; Belfi CA; Berger SJ; Berger NA
Cancer Res; 1997 Nov; 57(22):5112-6. PubMed ID: 9371511
[TBL] [Abstract][Full Text] [Related]
39. Novel amidine analogue of melphalan as a specific multifunctional inhibitor of growth and metabolism of human breast cancer cells.
Bielawski K; Bielawska A; Sosnowska K; Miltyk W; Winnicka K; Pałka J
Biochem Pharmacol; 2006 Jul; 72(3):320-31. PubMed ID: 16730667
[TBL] [Abstract][Full Text] [Related]
40. Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation.
Belfi CA; Chatterjee S; Gosky DM; Berger SJ; Berger NA
Biochem Biophys Res Commun; 1999 Apr; 257(2):361-8. PubMed ID: 10198218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]